Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success

Data ReadoutpositiveAlpha DaRTPembrolizumabPositive

AI Analysis

Summary

Alpha Tau reported positive data from a trial of Alpha DaRT in combination with Pembrolizumab for locally advanced or metastatic head and neck cancer, achieving 100% objective response rate and 18.2-month median overall survival, exceeding the study's pre-specified success threshold.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

100% objective response rate and 18.2-month median overall survival, surpassing pre-specified threshold for success

Importance:7/10

Sentiment:

0.85

clinical trialoncologyhead and neck cancerimmunotherapycombination therapypositive data

Related Companies

$DRTSW

Read the original article

Published by yahoo_finance on July 21, 2026 12:30 PM

Read Original